AptarGroup, Inc.

What they do

Aptar designs and manufactures dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions, and digital health products. It operates through three segments: Pharma, Beauty, and Closures, serving about 5,000 customers with no single customer over 4% of sales. The company has roughly 14,000 employees and facilities across North America, Europe, Asia, and Latin America.

Revenue drivers

• Pharma — Provides drug delivery systems, elastomeric components, and digital health solutions. Q2 2026 reported sales grew 4% with 1% core growth; strong in consumer healthcare, injectables, and prescription, partially offset by emergency medicine destocking.
• Beauty — Supplies dispensing and packaging for fragrance, color cosmetics, and hair care. Q2 2026 reported sales grew 10% (6% from acquisitions, 1% core), driven by prestige fragrance demand.
• Closures — Makes dispensing and non-dispensing closures for food and beverage. Q2 2026 reported sales rose 7% with 4% core growth, led by strong beverage sales, especially bottled water and a new dispensing closure innovation.

Recent performance

In Q2 2026, reported sales increased 6% to $1.03 billion, the first quarter over $1 billion, with core sales up 1%. Reported net income was $88 million and EPS $1.36, down from $1.67 a year ago. Adjusted EPS was $1.42 vs. $1.68, and adjusted EBITDA margin fell to 20.7% from 22.6%. For the first six months, sales rose 8% to $2.01 billion. The company returned $212 million year-to-date via dividends and buybacks.

Strategy

Aptar is investing in high-value segments like Pharma (including GLP-1 and biologics) and Closures innovation. Acquisitions (Sommaplast, BTY, Goldrain) expand capabilities in material science and beauty. Management emphasizes sustainability with recyclable and reusable products. They are executing operational improvements to restore margins, including managing product mix and production line ramps.

Risks

• Litigation and IP challenges — Ongoing patent infringement suits from Nemera (ophthalmic) and an antitrust suit from ARS Pharmaceuticals could distract management and incur costs.
• Regulatory and compliance burden — Products subject to FDA and global regulations; failure to comply could delay revenues or restrict product sales.
• Economic and geopolitical exposure — Global operations face risks from inflation, trade disputes, and political instability that could disrupt supply or demand.
• Margin compression from mix and input costs — Higher input costs and lower-margin product mix have pressured margins, and operational ramp-ups are creating temporary headwinds.

Outlook

Management remains confident in long-term margin structure despite current headwinds, citing strong demand in Pharma franchises, Closures momentum, and operational actions. They expect continued growth across segments, with Pharma benefiting from GLP-1 and biologics, and Beauty from prestige fragrance. Q2 2026 saw core sales growth of 1%, and they are focused on enhancing operational performance to drive margin recovery.